Celldex Therapeutics (CLDX) Income towards Parent Company (2010 - 2026)

Celldex Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$78.7 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 46.27% year-over-year to -$78.7 million; the TTM figure through Mar 2026 stood at -$283.6 million (down 58.59% YoY), while the FY2025 annual figure was -$258.8 million, down 63.91% from the prior year.
• Income towards Parent Company was -$78.7 million for Q1 2026 at Celldex Therapeutics, up from -$81.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$23.0 million in Q1 2022 to a low of -$81.3 million in Q4 2025.
• Historically, Income towards Parent Company has averaged -$44.1 million across 5 years, with a median of -$38.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 169.23% in 2022, then advanced 15.28% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at -$26.5 million in 2022, then sank by 63.5% to -$43.3 million in 2023, then declined by 8.74% to -$47.1 million in 2024, then sank by 72.68% to -$81.3 million in 2025, then increased by 3.24% to -$78.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$78.7 million (Q1 2026), -$81.3 million (Q4 2025), and -$67.0 million (Q3 2025), per Business Quant data.